Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 5α-reductase enzyme is a family of enzymes responsible for catalyzing the irreversible reduction of testosterone into dihydrotestosterone (DHT), a more potent androgen that plays a critical role in male sexual differentiation and development as well as in several androgen-dependent conditions. There are three known isoforms—type 1, type 2, and type 3—encoded by SRD5A genes. The enzyme is expressed in various tissues including reproductive organs, skin, liver, and nervous system. Inhibition or deficiency of this enzyme leads to significant clinical consequences related to androgen action such as ambiguous genitalia or reduced secondary male characteristics at birth.
Finasteride and dutasteride are competitive inhibitors of the 5α-reductase enzyme, blocking the conversion of testosterone to DHT, thereby reducing DHT levels in tissues.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5α-Reductase enzyme (5α-Reductase).